Product information leaflets
Product information on COVID-19 vaccines and medicines is available on this page.
This information is a copy of the product information for COVID-19 vaccines and medicines, which outlines the conditions under which the products should be used and information on its known safety.
This information may be updated, if necessary.
The MHRA is unable to offer medical advice and so if a patient has any questions about a vaccine they should contact their doctor or pharmacist. Suspected adverse reactions to a COVID-19 vaccine or medicine can be reported to us on a Yellow Card.
The Information for healthcare professionals document is a description of a medicinal product’s properties and the conditions attached to its use. It explains how to use and prescribe a medicine or vaccine. It is used by healthcare professionals, such as doctors, nurses and pharmacists.
The Information for UK recipients document provides information for patients. This is based on the Information for healthcare professionals of the product.
Vaccines
Information about the Pfizer/BioNTech COVID-19 vaccine (Comirnaty Omicron XBB.1.5), approved for supply by MHRA on 2 December 2020
Find out more about the approval from our press release.
Further details about the regulatory approval of Pfizer / BioNTech vaccine for COVID-19 can be found here. This includes:
Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 Vaccine
Information for UK recipients on Pfizer/BioNTech COVID-19 vaccine
Information about the Spikevax (formerly COVID-19 Vaccine Moderna), approved for supply by MHRA on 8th January 2021
Find out more about the approval from our press release.
Further details about the regulatory approval of Spikevax . This includes:
Information for Healthcare Professionals on Spikevax
Information for UK recipients on Spikevax
Information about the COVID-19 vaccine VidPrevtyn Beta, approved for supply by MHRA on 20 December 2022
Find out more about the approval from our press release.
Further details about the regulatory approval of COVID-19 vaccine VidPrevtyn Beta. This includes:
Information for Healthcare Professionals on COVID-19 vaccine VidPrevtyn Beta
Information for UK recipients on COVID-19 vaccine VidPrevtyn Beta
For information on any other COVID-19 vaccinations, please refer to the MHRA products website.
Therapeutics
Information about Molnupiravir, approved for supply by MHRA on 4th November 2021
Find out more about the approval from our press release.
Further details about the regulatory approval of Molnupiravir